-
1Academic Journal
Συγγραφείς: D. M. Pugaev, A. B. Ryabov, V. M. Khomyakov, I. V. Kolobaev, A. K. Kostrygin, O. A. Aleksandrov, G. S. Pogosуan, D. D. Sobolev, A. V. Chayka, A. B. Utkina, L. N. Lyubchenko, A. D. Kaprin, Д. М. Пугаев, А. Б. Рябов, В. М. Хомяков, И. В. Колобаев, А. К. Кострыгин, А. О. Александров, Г. С. Погосян, Д. Д. Соболев, А. В. Чайка, А. Б. Уткина, Л. Н. Любченко, А. Д. Каприн
Πηγή: Siberian journal of oncology; Том 23, № 6 (2024); 7-21 ; Сибирский онкологический журнал; Том 23, № 6 (2024); 7-21 ; 2312-3168 ; 1814-4861
Θεματικοί όροι: внутрибрюшная аэрозольная химиотерапия под давлением, multimodal treatment, hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC), pressurized intraperitoneal aerosol chemotherapy (PIPAC), комбинированное лечение, гипертермическая интраоперационная внутрибрюшная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/3359/1303; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020; 70(4): 313. doi:10.3322/caac.21609.; Camargo M.C., Anderson W.F., King J.B., Correa P., Thomas C.C., Rosenberg P.S., Eheman C.R., Rabkin C.S. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011; 60(12): 1644–9. doi:10.1136/gut.2010.236737.; Isobe T., Hashimoto K., Kizaki J., Miyagi M., Aoyagi K., Koufuji K., Shirouzu K. Characteristics and prognosis of gastric cancer in young patients. Oncol Rep. 2013; 30(1): 43–9. doi:10.3892/or.2013.2467.; Hsieh F.J., Wang Y.C., Hsu J.T., Liu K.H., Yeh C.N. Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger. J Surg Oncol. 2012; 105(3): 304–9. doi:10.1002/jso.22084.; Wang Z., Xu J., Shi Z., Shen X., Luo T., Bi J., Nie M. Clinicopathologic characteristics and prognostic of gastric cancer in young patients. Scand J Gastroenterol. 2016; 51(9): 1043–9. doi:10.1080/00365521.2016.1180707.; Lee J.H., Ryu K.W., Lee J.S., Lee J.R., Kim C.G., Choi I.J., Park S.R., Kook M.C., Kim Y.W., Bae J.M. Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly. J Surg Oncol. 2007; 95(6): 485–90. doi:10.1002/jso.20707.; Takatsu Y., Hiki N., Nunobe S., Ohashi M., Honda M., Yamaguchi T., Nakajima T., Sano T. Clinicopathological features of gastric cancer in young patients. Gastric Cancer. 2016; 19(2): 472–78. doi:10.1007/s10120-015-0484-1.; Rona K.A., Schwameis K., Zehetner J., Samakar K., Green K., Samaan J., Sandhu K., Bildzukewicz N., Katkhouda N., Lipham J.C. Gastric cancer in the young: An advanced disease with poor prognostic features. J Surg Oncol. 2017; 115(4): 371–75. doi:10.1002/jso.24533.; Kim K.H., Kim Y.M., Kim M.C., Jung G.J. Analysis of prognostic factors and outcomes of gastric cancer in younger patients: a case control study using propensity score methods. World J Gastroenterol. 2014; 20(12): 3369–75. doi:10.3748/wjg.v20.i12.3369.; Liu S., Feng F., Xu G., Liu Z., Tian Y., Guo M., Lian X., Cai L., Fan D., Zhang H. Clinicopathological features and prognosis of gastric cancer in young patients. BMC Cancer. 2016; 16: 478. doi:10.1186/s12885-016-2489-5.; Park J.C., Lee Y.C., Kim J.H., Kim Y.J., Lee S.K., Hyung W.J., Noh S.H., Kim C.B. Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol. 2009; 99(7): 395–401. doi:10.1002/jso.21281.; Smith B.R., Stabile B.E. Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg. 2009; 144(6): 506–10. doi:10.1001/archsurg.2009.77.; Saito H., Takaya S., Fukumoto Y., Osaki T., Tatebe S., Ikeguchi M. Clinicopathologic characteristics and prognosis of gastric cancer in young patients. Yonago Acta Med. 2012; 55(3): 57–61.; Zhou L., Jiang Z., Gu W., Han S. STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years. Medicine (Baltimore). 2021; 100(26). doi:10.1097/MD.0000000000026336.; Huang Q., Zheng X., Jiao Y., Lei Y., Li X., Bi F., Guo F., Wang G., Liu M. A Distinct Clinicopathological Feature and Prognosis of Young Gastric Cancer Patients Aged ≤ 45 Years Old. Front Oncol. 2021; 11. doi:10.3389/fonc.2021.674224.; Braga-Neto M.B., Carneiro J.G., de Castro Barbosa A.M., Silva I.S., Maia D.C., Maciel F.S., de Alcântara R.J.A., Vasconscelos P.R.L., Braga L.L.B.C. Clinical characteristics of distal gastric cancer in young adults from Northeastern Brazil. BMC Cancer. 2018; 18(1): 131. doi:10.1186/s12885-018-3995-4.; Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer. Report of the Adolescent and Young Adult Oncology Progress Review Group. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, LIVESTRONG Young Adult Alliance. 2006. 104 p.; Parsons H.M., Harlan L.C., Lynch C.F., Hamilton A.S., Wu X.C., Kato I., Schwartz S.M., Smith A.W., Keel G., Keegan T.H. Impact of cancer on work and education among adolescent and young adult cancer survivors. J Clin Oncol. 2012; 30(19): 2393–400. doi:10.1200/JCO.2011.39.6333.; Chung H.W., Noh S.H., Lim J.B. Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol. 2010; 16(2): 256–63. doi:10.3748/wjg.v16.i2.256.; Zhou F., Xu Y., Shi J., Lan X., Zou X., Wang L., Huang Q. Expression profile of E-cadherin, estrogen receptors, and P53 in early-onset gastric cancers. Cancer Med. 2016; 5(12): 3403–11. doi:10.1002/cam4.931.; Wang Z.K., Lin J.X., Li P., Xie J.W., Wang J.B., Lu J., Chen Q.Y., Cao L.L., Lin M., Tu R.H., Huang C.M., Zheng C.H. Higher Risk of Lymph Node Metastasis in Young Patients with Early Gastric Cancer. J Cancer. 2019; 10(18): 4389–96. doi:10.7150/jca.30260.; Al-Batran S.E., Homann N., Schmalenberg H., Kopp H.G., Haag G.M., Luley K.B., Schmiegel W.H., Folprecht G., Probst S., Prasnikar N., Thuss-Patience P.C., Fischbach W., Trojan J., Koenigsmann M., Pauligk C., Goetze T.O., Jaeger E., Meiler J., Schuler M.H., Hofheinz R. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J. Clin. Oncol. 2017; 35(s15).; Al-Batran S.E., Pauligk C., Homann N., Schmalenberg H., Kopp H., Haag G.M., Luley K., Folprecht G., Probst S., Thuss-Patience P., Trojan J., Koenigsmann M., Lindig U., Pohl M., Kasper S., Moehler M., Goetze T.O., Schuler M., Jaeger E., Hofheinz R.D. LBA27_PR: Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Ann. Oncol. 2017; 28(s5). doi:10.1093/annonc/mdx440.019.; Rompen I.F., Nienhüser H., Crnovrsanin N., Musa J., Haag G.M., Longerich T., Fiedler T., Müller-Stich B.P., Sisic L., Billeter A.T. Clinical Characteristics and Oncological Outcomes of Surgically Treated Early-Onset Gastric Adenocarcinoma – a Retrospective Cohort Study. J Cancer. 2023; 14(9): 1470–78. doi:10.7150/jca.82876.; Rau B., Lang H., Koenigsrainer A., Gockel I., Rau H.G., Seeliger H., Lerchenmueller C., Reim D., Wahba R., Angele M., Heeg S., Keck T., Weimann A., Topp S., Piso P., Brandl A., Schuele S., Jo P., Pratschke J., Wegel S., Rehders A., Moosmann N., Gaedcke J., Heinemann V., Trips E., Loeffler M., Schlag P.M., Thuss-Patience P. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial. J Clin Oncol. 2024; 42(2): 146–56. doi:10.1200/JCO.22.02867.; Маркович В.А., Тузиков С.А., Родионов Е.О., Попова Н.О., Цыганов М.М., Миллер С.В., Подолько Д.В., Цыденова И.А., Ибрагимова М.К., Литвяков Н.В. Комбинированное лечение больных раком желудка IV стадии с канцероматозом брюшины. Сибирский онкологический журнал. 2023; 22(1): 24–34. doi:10.21294/1814-4861-2023-22-1-24-34.; Case A., Prosser S., Peters C.J., Adams R., Gwynne S.; PIPAC UK Collaborative. Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: A systematic review by the PIPAC UK collaborative. Crit Rev Oncol Hematol. 2022; 180. doi:10.1016/j.critrevonc.2022.103846.; An H., Wang P.Y., Liu Y.C. Palliative Gastrectomy Improves the Survival of Patients with Metastatic Early-Onset Gastric Cancer: A Retrospective Cohort Study. Curr Oncol. 2023; 30(9): 7874–90. doi:10.3390/curroncol30090572.; https://www.siboncoj.ru/jour/article/view/3359
-
2Academic Journal
Συγγραφείς: A. S. Dzasokhov, A. A. Kostin, V. L. Astashov, A. V. Turiev, A. D. Uskov, А. С. Дзасохов, А. А. Костин, В. Л. Асташов, А. В. Туриев, А. Д. Усков
Πηγή: Research and Practical Medicine Journal; Том 10, № 1 (2023); 100-110 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 100-110 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1
Θεματικοί όροι: индекс перитонеального карциноматоза, ascites, peritoneal carcinomatosis, drug pathomorphosis, intraperitoneal chemotherapy, pressurized intraperitoneal aerosol chemotherapy, Peritoneal Cancer Index (PCI), асцит, перитонеальный канцероматоз, лекарственный патоморфоз, внутрибрюшная химиотерапия, внутрибрюшная аэрозольная химиотерапия под давлением
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/882/542; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.: МНИОИ им. П. А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022, 239 с. Доступно по: https://glavonco.ru/cancer_register/ЗИС%202021%20эл.%20версия.pdf. Дата обращения: 10.02.2023.; Степанов И. В., Падеров Ю.М., Афанасьев С. Г. Перитонеальный канцероматоз. Сибирский онкологический журнал. 2014;5:45–53.; Радостев С. И., Шелехов А. В., Дворниченко В. В., Мориков Д. Д., Расулов Р. И., Медведников А. А., Николаева Н. А. Результаты лечения больных раком яичников с явлениями перитонеального канцероматоза. Онкология. Журнал им. П.А. Герцена. 2020;9(6):5–11. https://doi.org/10.17116/onkolog202090615; Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. https://doi.org/10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313; Lowe KA, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M, Mowat FS, Goff B. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013 Jul;130(1):107–114. https://doi.org/10.1016/j.ygyno.2013.03.026; Chang SJ,Hodeib M,Chang J,Bristow RE.Survival impact of complete cytoreduction to no gross residual disease for advanced‑stage ovarian cancer: a meta‑analysis. Gynecol Oncol. 2013 Sep;130(3):493–498. https://doi.org/10.1016/j.ygyno.2013.05.040; Cortez AJ,Tudrej P,Kujawa KA,Lisowska KM.Advances in ovarian cancer therapy.Cancer Chemother Pharmacol.2018 Jan;81(1):17–38. https://doi.org/10.1007/s00280‑017‑3501‑8; Клинические рекомендации «Рак яичников, рак маточной трубы, первичный рак брюшины». М., Ассоциация онкологов России; 2020. Доступно по: https://oncology‑association.ru/wp‑content/uploads/2021/03/rak‑yaichnikov_matochnoj‑truby_. pdf. Дата обращения: 10.02.2023.; Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019 Mar 27;12(1):28. https://doi.org/10.1186/s13048‑019‑0503‑7; Cui R, Wang Y, Li Y, Li Y. Clinical value of ROMA index in diagnosis of ovarian cancer: meta‑analysis. Cancer Manag Res. 2019 Mar 28;11:2545–2551. https://doi.org/10.2147/cmar.s199400; Santotoribio JD, Garcia‑de la Torre A, Cañavate‑Solano C, Arce‑Matute F, Sanchez‑del Pino MJ, Perez‑Ramos S. Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors. Eur J Gynaecol Oncol. 2016;37(1):26–29.; Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019 Apr;43(2):135–144. https://doi.org/10.1016/j.currproblcancer.2018.06.001; Lertkhachonsuk AA, Buranawongtrakoon S, Lekskul N, Rermluk N, Wee‑Stekly WW, Charakorn C. Serum CA19‑9, CA‑125 and CEA as tumor markers for mucinous ovarian tumors. J Obstet Gynaecol Res. 2020 Nov;46(11):2287–2291. https://doi.org/10.1111/jog.14427; Grandi G, Fiocchi F, Cortesi L, Toss A, Boselli F, Sammarini M, et al. The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6‑month follow‑up program: results from a 6‑years surveillance. Menopause. 2021 Nov 1;29(1):63–72. https://doi.org/10.1097/gme.0000000000001883; Roze JF, Hoogendam JP, van de Wetering FT, Spijker R, Verleye L, Vlayen J, Veldhuis WB, Scholten RJ, Zweemer RP. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/ fallopian tube/primary peritoneal cancer. Cochrane Database Syst Rev. 2018 Oct 8;10(10):CD012567. https://doi.org/10.1002/14651858.cd012567.pub2; Wubulihasimu M, Maimaitusun M, Xu XL, Liu XD, Luo BM. The added value of contrast‑enhanced ultrasound to conventional ultrasound in differentiating benign and malignant solid breast lesions: a systematic review and meta‑analysis. Clin Radiol. 2018 Nov;73(11):936–943. https://doi.org/10.1016/j.crad.2018.06.004; Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020 Nov 9;371:m3773. https://doi.org/10.1136/bmj.m3773; Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 Oct;143(1):3–15. https://doi.org/10.1016/j.ygyno.2016.05.022; Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998 Apr‑May;14(3):254–261.; Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER‑O registry. Int J Gynecol Cancer. 2010 Jan;20(1):61–69. https://doi.org/10.1111/igc.0b013e3181c50cde; Narod S. Can advanced‑stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016 Apr;13(4):255–261. https://doi.org/10.1038/nrclinonc.2015.224; Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003 Jul;12(3):689–701.; Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY; HIPEC for Ovarian Cancer Collaborators. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg. 2022 May 1;157(5):374–383. https://doi.org/10.1001/jamasurg.2022.0143; El‑Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004 Mar‑Apr;6(2):117–127. https://doi.org/10.1593/neo.03205; González‑Moreno S, González‑Bayón LA, Ortega‑Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010 Feb 15;2(2):68–75. https://doi.org/10.4251/wjgo.v2.i2.68; de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res. 2007;169:53–73. https://doi.org/10.1007/978‑3‑540‑30760‑0_5; Reymond MA, Schneider C, Hohenberger W, Köckerling F. The pneumoperitoneum and its role in tumor seeding. Dig Surg. 1998;15(2):105–109. https://doi.org/10.1159/000018602; Reymond MA, Hu B, Garcia A, Reck T, Köckerling F, Hess J, Morel P. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc. 2000 Jan;14(1):51–55. https://doi.org/10.1007/s004649900010; Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012 Jul;26(7):1849–1855. https://doi.org/10.1007/s00464‑012‑2148‑0; Solass W, Herbette A, Schwarz T, Hetzel A, Sun JS, Dutreix M, Reymond MA. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012 Mar;26(3):847–852. https://doi.org/10.1007/s00464‑011‑1964‑y; Blanco A, Giger‑Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013 Jul;20(7):2311–2316. https://doi.org/10.1245/s10434‑012‑2840‑2; Solass W, Giger‑Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013 Oct;20(11):3504–3511. https://doi.org/10.1245/s10434‑013‑3039‑x; Solass W, Kerb R, Mürdter T, Giger‑Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014 Feb;21(2):553–559. https://doi.org/10.1245/s10434‑013‑3213‑1; Baert T, Ferrero A, Sehouli J, O’Donnell DM, González‑Martín A, Joly F, van der Velden J, Blecharz P, Tan DSP, Querleu D, Colombo N, du Bois A, Ledermann JA. The systemic treatment of recurrent ovarian cancer revisited. Ann Oncol. 2021 Jun;32(6):710–725. https://doi.org/10.1016/j.annonc.2021.02.015; Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger‑Pabst U, Zieren J, Rezniczek GA, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecol Oncol. 2015 May;137(2):223–228. https://doi.org/10.1016/j.ygyno.2015.02.009; Каприн А. Д., Хомяков В. М., Рябов А. Б., Болотина Л. В., Иванов А. В., Уткина А. Б., и др. Внутрибрюшная аэрозольная химиотерапия под давлением (ВАХД) – инновационный метод лечения больных с перитонеальным канцероматозом. Research’n Practical Medicine Journal. 2016;3(2):22–30. https://doi.org/10.17709/2409‑2231‑2016‑3‑2‑3; Nowacki M, Alyami M, Villeneuve L, Mercier F, Hubner M, Willaert W, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study. Eur J Surg Oncol. 2018 Jul;44(7):991–996. https://doi.org/10.1016/j.ejso.2018.02.014; Дзасохов А. С., Костин А. А., Асташов В. Л., Хомяков В. М., Усков А. Д., Андреева М. А., Уткина А. Б. Описание первого клинического случая комбинации хирургической циторедукции и внутрибрюшной аэрозольной химиотерапии под давлением при лечении рака яичников. Онкология. Журнал им. П.А. Герцена. 2021;10(2):44–49. https://doi.org/10.17116/onkolog20211002144; https://www.rpmj.ru/rpmj/article/view/882
-
3Academic Journal
Συγγραφείς: V. A. Markovich, S. A. Tuzikov, E. O. Rodionov, N. V. Litvyakov, N. O. Popova, M. M. Tsyganov, L. V. Levonyan, S. V. Miller, D. V. Podolko, I. A. Tsydenova, M. K. Ibragimova, В. А. Маркович, С. А. Тузиков, Е. О. Родионов, Н. В. Литвяков, Н. О. Попова, М. М. Цыганов, Л. В. Левонян, С. В. Миллер, Д. В. Подолько, И. А. Цыденова, М. К. Ибрагимова
Πηγή: Siberian journal of oncology; Том 20, № 6 (2021); 104-113 ; Сибирский онкологический журнал; Том 20, № 6 (2021); 104-113 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-6
Θεματικοί όροι: внутрибрюшная аэрозольная химиотерапия, cytoreductive surgery, hyperthermic intraoperative intraperitoneal chemotherapy, intraperitoneal aerosol chemotherapy, циторедуктивная хирургия, гипертермическая интраоперационная внутрибрюшная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1992/936; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi:10.3322/caac.21492.; Worldwide cancer data. [Internet]. URL: https://www.wcrf.org/dietandcancer/worldwide-cancer-data/ (cited 01.2019).; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М., 2020. 252 с.; El-Sedfy A., Brar S.S., Coburn N.G. Current role of minimally invasive approaches in the treatment of early gastric cancer. World J Gastroenterol. 2014 Apr 14; 20(14): 3880–8. doi:10.3748/wjg.v20.i14.3880.; Ellebaek S.B., Graversen M., Detlefsen S., Lundell L., Fristrup C.W., Pfeiffer P., Mortensen M.B. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. Clin Exp Metastasis. 2020; 37: 325–32. doi:10.1007/s10585-020-10023-5.; Хомяков В.М., Рябов А.Б., Болотина Л.В., Соболев Д.Д., Уткина А.Б., Кузнецова О.С. Лечение больных раком желудка с канцероматозом брюшины. Современный взгляд и перспективы. Онкология. Журнал им. П.А. Герцена. 2017. 6(6): 4–13.; Fujitani K., Yang H.-K., Mizusawa J., Kim Y.-W., Terashima M., Han S.-U., Iwasaki Y., Hyung W.J., Takagane A., Park D.J., Yoshikawa T., Hahn S., Nakamura K., Park C.H., Kurokawa Y., Bang Y.-J., Park B.J., Sasako M., Tsujinaka T., REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomized controlled trial. Lancet Oncol. 2016 Mar; 17(3): 309–18. doi:10.1016/S1470-2045(15)00553-7.; Калинин А.Е., Гущин В.В. Принятие хирургических решений при лечении больных метастатическими злокачественными опухолями. Хирургическое лечение перитонеального канцероматоза. Практическая онкология. 2016. 17(3): 119–28.; Amin M.B., Greene F.L., Edge S.B., Compton C.C., Gershenwald J.E., Brookland R.K., Meyer L., Gress D.M., Byrd D.R., Winchester D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more «personalized» approach to cancer staging. CA Cancer J Clin. 2017 Mar; 67(2): 93–9. doi:10.3322/caac.21388.; Gamboa A.C., Winer J.H. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers. 2019; 11: 1662. doi:10.3390/cancers11111662.; Glehen O., Passot G., Villeneuve L., Vaudoyer D., Bin-Dorel S., Boschetti G., Piaton E., Garofalo A. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014; 14: 183.; Yonemura Y., Canbay E., Ishibashi H., Hirano M., Mizumoto A., Takao N., Ichinose M., Noguchi K., Motoi S., Liu Y., Wakama S., Coccolini F., Taniguchi K. Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Metastasis of Gastric Cancer. Cancer Regional Therapy. 2020. doi:10.1007/978-3-030-28891-4_10.; Brücher B.L., Piso P., Verwaal V., Esquivel J., Derraco M., Yonemura Y., Gonzalez-Moreno S., Pelz J., Königsrainer A., Ströhlein M., Levine E.A., Morris D., Bartlett D., Glehen O., Garofalo A., Nissan A. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC-overview and basics. Cancer Invest. 2012 Mar; 30(3): 209–24. doi:10.3109/07357907.2012.654871.; Maeda H., Kobayashi M., Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol. 2015 Oct 21; 21(39): 10936–47. doi:10.3748/wjg.v21.i39.10936.; National Comprehensive Cancer Network (NCCN). [Internet]. URL: https://www.nccn.org/professionals/physician_gls/default.aspx (cited 18.10.2019).; Yonemura Y., Prabhu A., Sako S., Ishibashi H., Mizumoto A., Takao N., Ichinose M., Motoi S., Liu Y., Nishihara K., Brandl A., Fushida S. Long Term Survival after Cytoreductive Surgery Combined with Perioperative Chemotherapy in Gastric Cancer Patients with Peritoneal Metastasis. Cancers. 2020; 12 (1): 116. doi:10.3390/cancers12010116.; Афанасьев С.Г., Добродеев А.Ю. Циторедуктивные операции (Нужно ли удалять первичную опухоль? Где предел разумной циторедукции? Практическая онкология. 2014; 15(2): 93–100.; Sugarbaker P.H., Van der Smitten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016; 7: 29–44. doi:10.3978/j.issn.2078-6891.2015.105.; Kono K., Yong W.P., Okayama H., Shabbir A., Momma T., Ohki S., Takenoshita S., So J. Intraperitoneal chemotherapy for stomach cancer with peritoneal disease: the experience of Singapore and Japan. Gastric Cancer. 2017; 20: 122–7. doi:10.1007/s10120-016-0660-y.; Walker J.L., Brady M.F., Wenzel L., Fleming G.F., Huang H.Q., DiSilvestro P.A., Fujiwara K., Alberts D.S., Zheng W., Tewari K.S., Cohn D.E., Powell M.A., Van Le L., Davidson S.A., Gray H.J., Rose P.G., Aghajanian C., Myers T., Alvarez Secord A., Rubin S.C., Mannel R.S. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 Jun 1; 37(16): 1380–90. doi:10.1200/JCO.18.01568.; Cascales-Campos P.A., López-López V., Torres-Melero J., Arjona A., Muñoz-Casares F.C., Barrios P., Morales R., Pereira F., Bretcha-Boix P., González-Bayón L., González-Moreno S., Gil J. Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP). Clin Transl Oncol. 2020; 22: 130–6. doi:10.1007/s12094-019-02124-9.; Quenet F., Elias D., Roca L., Goere D., Ghouti L., Pocard M., Facy O., Arvieux C., Lorimier G., Pezet D., Marchal F., Loi V., Meeus P., Forges H.D., Stanbury T., Paineau J., Glehen O.A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018; 39:1.; Armstrong D.K., Walker J.L. Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. J Clin Oncol. 2019; 37(27): 2416–9.; Yoshida K., Yamaguchi K., Okumura N., Tanahashi T., Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016 Apr; 19(2): 329–38. doi:10.1007/s10120-015-0575-z.; Ansari N., Chandrakumaran K., Dayal S., Mohamed F., Cecil T.D., Moran B.J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016 Jul; 42(7): 1035–41. doi:10.1016/j.ejso.2016.03.017.; Sugarbaker P.H. Prevention and Treatment of Peritoneal Metastases from Gastric Cancer. J Clin Med. 2021; 10(9): 1899. doi:10.3390/jcm10091899.; The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. Cancer. 2020; 126(11): 2541–6. doi:10.1002/cncr.32868.; Al-Batran S.E., Homann N., Pauligk C., Illerhaus G., Martens U.M., Stoehlmacher J., Schmalenberg H., Luley K.B., Prasnikar N., Egger M., Probst S., Messmann H., Moehler M., Fischbach W., Hartmann J.T., Mayer F., Höffkes H.-G., Koenigsmann M., Arnold D., Kraus T.W., Grimm K., Berkhoff S., Post S., Jäger E., Bechstein W., Ronellenfitsch U., Mönig S., Hofheinz R.D. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017 Sep 1; 3(9):1237–44. doi:10.1001/jamaoncol.2017.0515.; Хомяков В.М., Соболев Д.Д., Колобаев И.В., Чайка А.В., Уткина А.Б., Корниецкая А.Л., Виндиза Ф.Р., Рябов А.Б. Конверсионная хирургия при раке желудка IV cтадии. Обзор литературы и опыт МНИОИ Им. П.А. Герцена. Вопросы онкологии. 2020; 66(1). С. 50–7.; Sun F., Feng M., Guan W. Mechanisms of peritoneal dissemination in gastric cancer. Oncol Lett. 2017 Dec; 14(6):6991–8. doi:10.3892/ol.2017.7149.; Yonemura Y., Iahibashi H., Sako S., Mizumoto A., Takao N., Ichinose M., Motoi S., Liu Y., Wakama S., Kamada Y., Nishihara K. Advances with pharmacotherapy for peritoneal metastasis. Exp Opin Pharmacother. 2020; 21(16): 2057–66. doi:10.1080/14656566.2020.1793957.; Chia C.S., You B., Decullier E., Vaudoyer D., Lorimier G., Abboud K., Bereder J.-M., Arvieux C., Boschetti G., Glehen O., BIG RENAPE Group. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol. 2016 Jun; 23(6): 1971–9. doi:10.1245/s10434-015-5081-3.; Intraperitoneal Aerosol Chemotherapy in Gastric Cancer (PIPACGA01). [Internet]. URL: https://clinicaltrials.gov/ct2/show/NCT01854255 (cited 04.01.2018).; Bonnot P.E., Piessen G., Pocard M., Meunier B., Bereder J.M., Abboud K., Marchal F., Quenet F., Goere D., Msika S., Arvieux C., Pirro N., Wernert R., RAT P., Pezet D., Lefevre J., Courvoisier T., Kianmanesh R., Meeus P., Glehen O.; FREGAT and BIG-RENAPE Networks. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. J Clin Oncol. 2019 Aug 10; 37(23): 2028–40. doi:10.1200/JCO.18.01688.; Newhook T.E., Agnes A., Blum M., Estrella J.S., Das P., Ho L., Ajani J.A., Minsky B.D., Mansfield P., Badgwell B.D. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 May; 26(5): 1394–1400. doi:10.1245/s10434-018-07140-7.; Badgwell B., Blum M., Das P., Estrella J., Wang X., Ho L., Fournier K., Royal R., Mansfield P., Ajani J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11): 3338–44. doi:10.1245/s10434-017-6047-4.; Solass W., Kerb R., Mürdter T., Giger-Pabst U., Strumberg D., Tempfer C., Zieren J., Schwab M., Reymond M.A. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014 Feb; 21(2): 553–9. doi:10.1245/s10434-013-3213-1.; Каприн А.Д., Хомяков В.М., Рябов А.Б., Болотина Л.В., Иванов А.В., Черемисов В.В., Колобаев И.В., Чайка А.В., Соболев Д.Д., Крамская Л.В., Уткина А.Б. Внутрибрюшная аэрозольная химиотерапия под давлением у больных диссеминированным раком желудка. Онкология. Журнал им. П.А. Герцена. 2016; 5(2): 12–8. doi:10.17116/onkolog20165212-18.; Dakwar G.R., Shariati M., Willaert W., Ceelen W., de Smedt S.C., Remaut K. Nanomedicine – based intraperitoneal therapy for the treatment of peritoneal carcinomatosis – Mission possible? Adv Drug Deliv Rev. 2017 Jan 1; 108: 13–24. doi:10.1016/j.addr.2016.07.001.; Хомяков В.М., Рябов А.Б., Колобаев И.В., Болотина Л.В., Уткина А.Б., Соболев Д.Д., Кузнецова О.С., Каприн А.Д. Внутрибрюшная аэрозольная химиотерапия под давлением в сочетании с системной химиотерапией – новый подход в лечении больных раком желудка с перитонеальным карциноматозом. Сибирский онкологический журнал. 2020; 19(4): 49–58. doi:10.21294/1814-4861-2020-19-4-49-58; Graversen M., Detlefsen S., Bjerregaard J.K., Fristrup C.W., Pfeiffer P., Mortensen M.B. Prospective, single–center implementation and evaluation of intraperitoneal aerosol pressure chemotherapy (PIPAC) response for peritoneal metastases. Adv Med Oncol. 2018. doi:10.1177/1758835918777036.; Solass W., Sempoux C., Carr N.J., Bibeau F., Neureiter D., Jäger T., Caterino T.D., Brunel C., Klieser E., Fristrup C.W., Mortensen M.B., Detlefsen S. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019 Jun; 74(7): 1014–24. doi:10.1111/his.13829.; Thomassen I., van Gestel Y.R., van Ramshorst B., Luyer M.D., Bosscha K., Nienhuijs S.W., Lemmens V.E., de Hingh I.H. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014 Feb 1; 134(3): 622–8. doi:10.1002/ijc.28373.; Ji Z.-H., Peng K.-W., Yu Y., Li X.-B., Yonemura Y., Liu Y., Sugarbaker P.H., Li Y. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017 Aug; 33(5): 562–70. doi:10.1080/02656736.2017.1283065.; Seshadri R.A., Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for stomach cancer. World J Gastroenterol 2016, 22: 1114–30.; Levine E.A., Stewart J.H., Shen P., Russell G.B., Loggie B.L., Votanopoulos K.I. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014 Apr; 218(4): 573–85. doi:10.1016/j.jamcollsurg.2013.12.013.; Coccolini F., Campanati L., Catena F., Ceni V., Ceresoli M., Jimenez Cruz J., Lotti M., Magnone S., Napoli J., Rossetti D., De Iaco P., Frigerio L., Pinna A., Runnebaum I., Ansaloni L. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol. 2015 Jan; 26(1): 54–61. doi:10.3802/jgo.2015.26.1.54.; https://www.siboncoj.ru/jour/article/view/1992
-
4Academic Journal
Συγγραφείς: A. D. Kaprin, V. M. Khomyakov, D. D. Sobolev, L. V. Bolotina, A. B. Ryabov, V. E. Khoronenko, M. M. Soboleva, L. V. Kramskaya, А. Д. Каприн, В. М. Хомяков, Д. Д. Соболев, Л. В. Болотина, А. Б. Рябов, В. Э. Хороненко, М. М. Соболева, Л. В. Крамская
Πηγή: Research and Practical Medicine Journal; Том 2, № 4 (2015); 17-27 ; Research'n Practical Medicine Journal; Том 2, № 4 (2015); 17-27 ; 2410-1893 ; 10.17709/2409-2231-2015-4
Θεματικοί όροι: адьювантная химиотерапия, dissemination, hyperthermic intraperitoneal chemotherapy, adjuvant chemotherapy, диссеминация, гипертермическая интраоперационная внутрибрюшная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/97/104; Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010; 60 (5): 277–300.; Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M. Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010; 15;127 (12): 893–917.; López-Basave H. N., Morales-Vásquez F., Ruiz-Molina J. M., Namendys-Silva S. A., Vela-Sarmiento I., Ruan J. M., Rosciano A. E., Calderillo-Ruiz G., Díaz-Romero C., Herrera-Gómez A., Meneses-García A. A. Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis? Cancer Manag Res. 2013; 4;5: 1–6.; Каприн А. Д., Старинский В. В., Петрова Г. В., 2015. (ред). Состояние онкологической помощи населению России в 2013. М., 2013.; Kaibara N., Sumi K., Yonekawa M., Ohta M., Makino M., Kimura O., Nishidoi H., Koga S. Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer? Am. J. Surg. 1990; 159 (2): 18–21.; Онкология: национальное руководство. Под ред. Чиссова В. И., Давыдова М. И. М.: ГЭОТАР-Медиа, 2008.; Oh D. Y., Bang Y. J. Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol. 2013; 14 (3): 311–320.; Taketa T., Sudo K., Wadhawa R., Blum M. M., Ajani J. A. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013; 15 (2): 146–151.; Gordon M. A., Gundacker H. M., Benedetti J., Macdonald J. S., Baranda J. C., Levin W. J., Blanke C. D., Elatre W., Weng P., Zhou J. Y., Lenz H. J., Press M. F. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT‑0116/SWOG9008 clinical trial. Ann Oncol. 2013; 24 (7): 1754–1761.; Chu D. Z., Lang N. P., Thompson C., Osteen P. K., Westbrook K. C. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989; 63 (2): 364–367.; Eltabbakh G. H., Werness B. A., Piver S., Blumenson L. E. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol. 1998; 71 (2): 230–239.; Puhlmann M., Fink U., Siewert J. R. Value of tumor debulking in gastrointestinal tumors. Chirurg. 1999; 70 (12): 1408–1414.; Makino M., Kaibara N., Kimura O., Nishidoi H., Koga S. Correlation between subserosal venous invasion by gastric cancer and the occurrence of liver metastasis. Am J Clin Oncol. 1989; 12 (5): 407–410.; Bozzetti F., Bonfanti G., Audisio R. A., Doci R., Dossena G., Gennari L., Andreola S. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet. 1987; 164 (2): 151–154.; Santoro E., Garofalo A., Carlini M., Rinaldi G., Santoro E. Early and late results of 100 consecutive total gastrectomies for cancer. Hepatogastroenterology. 1994; 41 (5): 489–496.; Sugarbaker P. H. Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. Michig an: Ludann Company, 1998.; Sadeghi B., Arvieux C., Glehen O., Beaujard A. C., Rivoire M., Baulieux J., Fontaumard E., Brachet A., Caillot J. L., Faure J. L., Porcheron J., Peix J. L., François Y., Vignal J., Gilly F. N. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88 (2): 358–363.; Jacquet P., Vidal-Jove J., Zhu B. W., Sugarbaker P. Peritoneal carcinomatosis from intraabdominal malignancy: natural history and new prospects for management. Acta Belg Chir. 1994; 94 (4): 191–197.; Jacquet P., Stuart O. A., Chang D., Sugarbaker P. H. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996; 7 (5): 596–603.; Sugarbaker P. H. Review of a personal experience in the management of carcinomatosis and sarcomatosis Jpn J Clin Oncol. 2001; 31 (12): 573–583.; Beaujard A. C., Glehen O., Caillot J. L., Francois Y., Bienvenu J., Panteix G., Garbit F., Grandclément E., Vignal J., Gilly F. N. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000; 88 (11): 2512–2519.; Ceelen W. P., Flessner M. F. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010; 7 (2): 108–115.; Lippmann H. G., Graichen D., Sarembe B., Schmidt D., Löffler I., Schilling W., Preissler J. Clinical examination of the conception ‘86 of «Canсer Multistep-Therapie» (CMT) by M. v. Ardene. Arch Geschwulstforsch. 1976; 46 (7): 568–609.; Spratt J. S., Adcock R. A., Muskovin M., Sherrill W., McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980; 40 (2): 256–60.; Athanasoulis C. A., Baum S., Rösch J., Waltman A. C., Ring E. J., Smith J. C. Jr, Sugarbaker E., Wood W. Mesenteric arterial infusions of vasopressin for hemorrhage from colonic diverticulosis. Am J Surg. 1975; 129 (2): 212–6.; Storm F. K. Clinical hyperthermia and chemotherapy. Radiol Clin North Am. 1989; 27 (3): 621–7.; Jacquet P., Stephens A. D., Averbach A. M., Chang D., Ettinghausen S. E., Dalton R.R, Steves M. A., Sugarbaker P. H. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996; 77 (12): 2622–2629.; Kunisaki C., Shimada H., Nomura M, Matsuda G., Otsuka Y., Akiyama H. Therapeutic strategy for signet ring cell carcinoma of the stomach. Br J Surg. 2004; 91 (10):1319–1324.; Kochi M., Fujii M., Kanamori N., Kaiga T., Takahashi T., Kobayashi M., Takayama T. Neoadjuvant chemotherapy with S‑1 and CDDP in advanced gastric cancer. J Cancer Res Clin Oncol. 2006; 132 (12): 781–785.; Costa W. L., Jr, Coimbra F. J., Ribeiro H. S., Diniz A. L., de Godoy A. L., Begnami M., Silva M. J., Fanelli M. F., Mello C. A. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol. 2012; 19 (10): 195.; https://www.rpmj.ru/rpmj/article/view/97
-
5Academic Journal
Συγγραφείς: Yu. A. Shelygin, S. I. Achkasov, A. F. Filon, L. P. Orlova, V. V. Veselov, I. V. Zarodnyuk, Ю. А. Шелыгин, С. И. Ачкасов, А. Ф. Филон, Л. П. Орлова, В. В. Веселов, И. В. Зароднюк
Πηγή: Malignant tumours; № 2 (2013); 107-113 ; Злокачественные опухоли; № 2 (2013); 107-113 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: внутрибрюшная химиотерапия, combined operations, intraperitoneal chemotherapy, комбинированные операции
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/41/45; Чиссов В. И., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2010 году. М.: ФГУ «МНИОИ им. П. А. Герцена» Минздравсоцразвития России, 2011. — С. 68-75.; Akiyoshi T, Fujimoto Y, Konishi T, Kuroyanagi H, Ueno M, Oya M, Miyata S; Yamaguchi T. Prognostic factors for survival after salvage surgery for locoregional recurrence of colon cancer. Am J Surg. 2011 Jun; 201 (6): 726-33.; Bowne WB, Lee B, Wong WD, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases. Dis Colon Rectum 2005; 48: 897-909.; Carne PW, Frye JN, Kennedy-Smith A, et al. Local invasion of the bladder with colorectal cancers: surgical management and patterns of local recurrence. Dis Colon Rectum 2004; 47: 44-47.; Croner RS, Merkel S, Papadopoulos T, et al. Multivisceral resection for colon carcinoma. Dis Colon Rectum. 2009 Aug; 52 (8): 1381-6.; Downing A, Aravani A, Macleod U, Oliver S, Finan PJ, Thomas JD, Quirke P, Wilkinson JR, Morris EJ. Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in the first year after diagnosis. Br J Cancer. 2013 Feb 19; 108 (3): 681-5.; Elferink MA, Visser O, Wiggers T, et al. Prognostic factors for locoregional recurrences in colon cancer. Ann Surg Oncol. 2012 Jul; 19 (7): 2203-11.; Harris G. J., Church J. M., et al. Factors affecting local recurrence of colonic adenocarcinoma. // Dis. Colon Rectum. 2002. 45 (8): 1029-34.; Hida J, Yasutomi M, Shindoh K, et al. Second-look operation for recurrent colorectal cancer based on carcino-embryonic antigen and imaging techniques. Dis Colon Rectum 1996; 39: 74-79.; Jemal A., Murray T., Warel B, et al. Cancer Statistic 2005. CA Cancer J Clin. 2005; 55: 10-30.; Koea JB, Lanouette N, Paty PB, et al. Abdominal wall recurrence after colorectal resection for cancer. Dis Colon Rectum 2000; 43: 628-632.; Meropol NJ, Berger NA. Colon cancer recurrence: insights from the interface between epidemiology, laboratory science, and clinical medicine. J Natl Cancer Inst. 2012 Nov 21; 104 (22): 1697-8.; Platell C, Ng S, et al. Changing management and survival in patients with stage IV colorectal cancer. Dis Colon Rectum. 2011, 54: 214-9.; Taylor WE, Donohue JH, Gunderson LL, et al. The Mayo clinic experience with multimodality treatment of locally advanced or recurrent colon cancer. Ann Surg Oncol 2002; 9: 177-185.; Yamamoto Y, Imai H, Iwamoto S, et al. Surgical treatment of the recurrence of colorectal cancer. Jpn J Surg 1996; 26: 164-168.; https://www.malignanttumors.org/jour/article/view/41
-
6Academic Journal
Συγγραφείς: Хороненко, В., Шеметова, Мария, Дрожжина, О., Хомяков, В., Соболев, Д.
Θεματικοί όροι: ГИПЕРТЕРМИЧЕСКАЯ ИНТРАОПЕРАЦИОННАЯ ВНУТРИБРЮШНАЯ ХИМИОТЕРАПИЯ, ПРЕДОПЕРАЦИОННАЯ ПОДГОТОВКА, ПЕРИТОНЕАЛЬНЫЙ КАНЦЕРОМАТОЗ, ЛЕЧЕНИЕ ДИССЕМИНИРОВАННОГО РАКА ЖЕЛУДКА, АНЕСТЕЗИЯ
Περιγραφή αρχείου: text/html
-
7Academic Journal
Συγγραφείς: Соболев Дмитрий Дмитриевич, Каприн Андрей Дмитриевич, Хомяков Владимир Михайлович, Болотина Лариса Владимировна, Рябов Андрей Борисович, Хороненко Виктория Эдуардовна, Соболева Мария Михайловна, Крамская Людмила Викторовна
Θεματικοί όροι: рак желудка, диссеминация, гипертермическая интраоперационная внутрибрюшная химиотерапия, адьювантная химиотерапия
Περιγραφή αρχείου: text/html
-
8Academic Journal
Συγγραφείς: ШЕЛЫГИН Ю.А., АЧКАСОВ С.И., ФИЛОН А.Ф., ОРЛОВА Л.П., ВЕСЕЛОВ В.В., ЗАРОДНЮК И.В.
Θεματικοί όροι: МЕСТНЫЕ РЕЦИДИВЫ РАКА ОБОДОЧНОЙ КИШКИ,КОМБИНИРОВАННЫЕ ОПЕРАЦИИ,ВНУТРИБРЮШНАЯ ХИМИОТЕРАПИЯ
Περιγραφή αρχείου: text/html
-
9Academic Journal
Πηγή: Анестезиология и реаниматология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, ГИПЕРТЕРМИЧЕСКАЯ ИНТРАОПЕРАЦИОННАЯ ВНУТРИБРЮШНАЯ ХИМИОТЕРАПИЯ, ПРЕДОПЕРАЦИОННАЯ ПОДГОТОВКА, ПЕРИТОНЕАЛЬНЫЙ КАНЦЕРОМАТОЗ, ЛЕЧЕНИЕ ДИССЕМИНИРОВАННОГО РАКА ЖЕЛУДКА, АНЕСТЕЗИЯ, 3. Good health
Περιγραφή αρχείου: text/html
-
10Academic Journal
Πηγή: Research'n Practical Medicine Journal.
Θεματικοί όροι: рак желудка, диссеминация, гипертермическая интраоперационная внутрибрюшная химиотерапия, адьювантная химиотерапия, 3. Good health
Περιγραφή αρχείου: text/html
-
11Academic Journal
Πηγή: Злокачественные опухоли.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, МЕСТНЫЕ РЕЦИДИВЫ РАКА ОБОДОЧНОЙ КИШКИ,КОМБИНИРОВАННЫЕ ОПЕРАЦИИ,ВНУТРИБРЮШНАЯ ХИМИОТЕРАПИЯ
Περιγραφή αρχείου: text/html
